Search Results

ABBV AbbVie Inc. - Fundamental Analysis

NEUTRAL
Sign in to save Save this symbol to a watchlist or track a position.
ABBV Stock | Fundamental Analysis & Investment Insights
NYSE Healthcare Drug Manufacturers - General
Current Price Live
$219.26
Analyst Target
$245.22
+11.8% Upside
52W High
$244.81
52W Low
$164.39

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Jan 24, 2026
Market cap
$387.52B
P/E
163.63
ROE
138.0%
Profit margin
4.0%
Debt/Equity
N/A
Dividend yield
3.05%

AI Analysis

Powered by advanced machine learning algorithms

Confidence Score
68%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Key Strengths

High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Attractive dividend yield (3.05%) above market average
Analyst consensus supports upside with target price 11.8% above current level

Key Risks

Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
Weak liquidity position with current ratio (0.72) and quick ratio (0.47) below 1.0
Bearish insider sentiment with $11.05M in net sales and zero buys in last 6 months
AI Fair Value Estimate
Based on comprehensive analysis
$9.38
-95.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
45
Moderate
Value
32
Future
48
Past
65
Health
41
Dividend
38
AI Verdict
Neutral with caution
Key drivers: High forward growth expectations priced in, Deteriorating earnings quality, Strong revenue momentum, Dividend sustainability concerns, Analyst optimism vs insider skepticism
Confidence
72%
Value
32/100

Ref P/E, PEG, Graham Number

Positives
  • Forward P/E of 15.42 is reasonable for healthcare sector
Watchpoints
  • Current P/E of 163.63 is extremely elevated
  • Price/Book is negative (-146.66), indicating accounting distress
  • Graham Number unavailable, Intrinsic Value ($9.38) far below market price
Future
48/100

Ref Growth rates

Positives
  • Revenue growth (9.10% YoY) remains solid
Watchpoints
  • Earnings growth collapsing (YoY: -88.70%)
  • Q/Q earnings down 88.10%, signaling sharp downturn
Past
65/100

Ref Historical trends

Positives
  • Consistent earnings beat history (22/25 quarters)
  • Strong 5-year price appreciation (+140.3%)
  • Operating margin stable near 35.5%
Watchpoints
  • Recent EPS growth turning sharply negative
Health
41/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • ROE of 137.96% suggests aggressive capital efficiency (though potentially debt-driven)
Watchpoints
  • Piotroski F-Score of 4/9 indicates weak financial health
  • Current ratio (0.72) and quick ratio (0.47) signal liquidity risk
  • Altman Z-Score unavailable, increasing uncertainty
Dividend
38/100

Ref Yield, Payout

Positives
  • Dividend yield of 3.05% is attractive
Watchpoints
  • Payout ratio of 490.15% is unsustainable
  • Dividend Strength score of 20/100 indicates high risk

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$219.26
Analyst Target
$245.22
Upside/Downside
+11.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ABBV and closest competitors.

Updated 2026-01-23
Company 5Y 3Y 1Y 6M 1M 1W
ABBV
AbbVie Inc.
Primary
+140.3% +65.5% +32.8% +17.0% -3.9% +2.3%
UNH
UnitedHealth Group Incorporated
Peer
+2.0% -27.9% -33.6% +18.6% -0.2% -3.8%
AZN
AstraZeneca PLC
Peer
+92.9% +49.4% +38.4% +28.8% +0.5% -1.5%
MRK
Merck & Co., Inc.
Peer
+60.7% +8.0% +12.1% +38.6% +9.7% -1.5%
JNJ
Johnson & Johnson
Peer
+54.8% +39.0% +52.5% +35.4% +4.0% +7.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
163.63
Forward P/E
15.42
PEG Ratio
N/A
P/B Ratio
-146.66
P/S Ratio
6.5
EV/Revenue
7.56
EV/EBITDA
15.27
Market Cap
$387.52B

Profitability

Profit margins and return metrics

Profit Margin 4.0%
Operating Margin 35.5%
Gross Margin 71.46%
ROE 137.96%
ROA 9.59%

Growth

Revenue and earnings growth rates

Revenue Growth +9.1%
Earnings Growth -88.7%
Q/Q Revenue Growth N/A
Q/Q Earnings Growth -88.1%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.72
Weak
Quick Ratio
0.47
Poor
Cash/Share
$3.21

Quarterly Earnings History

EPS performance vs analyst estimates

2026-02-04
$N/A
2025-10-31
$1.86
+4.2% surprise
2025-07-31
$2.97
+2.1% surprise
2025-04-25
$2.46
+2.6% surprise

Healthcare Sector Comparison

Comparing ABBV against 146 companies in the Healthcare sector (11 bullish, 60 neutral, 75 bearish)
P/E Ratio
163.63
This Stock
vs
197.75
Sector Avg
-17.3% (Discount)
Return on Equity (ROE)
137.96%
This Stock
vs
-56.86%
Sector Avg
-342.6% (Below Avg)
Profit Margin
4.0%
This Stock
vs
-20.8%
Sector Avg
-119.3% (Weaker)
Revenue Growth
9.1%
This Stock
vs
62.23%
Sector Avg
-85.4% (Slower)
Current Ratio
0.72
This Stock
vs
3.45
Sector Avg
-79.0% (Weaker)

Similar Companies

Peer comparison within the same industry

Company AI Rating Market Cap P/E ROE Profit Margin Price
ABBV
AbbVie Inc.
NEUTRAL $387.52B 163.63 138.0% 4.0% $219.26
UNH
UnitedHealth Group Incorporated
NEUTRAL $299.85B 17.25 17.5% 4.0% $331.02
AZN
AstraZeneca PLC
NEUTRAL $288.2B 30.48 21.7% 16.2% $92.95
MRK
Merck & Co., Inc.
NEUTRAL $271.83B 14.4 39.5% 29.6% $108.83
JNJ
Johnson & Johnson
NEUTRAL $526.82B 21.15 33.6% 27.3% $218.66

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date Insider Position Transaction Shares Value
2025-08-12 SALEKI-GERHARDT AZITA Chief Operating Officer Option Exercise 42,370 $2,324,418
2025-08-12 SALEKI-GERHARDT AZITA Chief Operating Officer Sale 42,370 $8,407,055
2025-08-05 DONOGHOE NICHOLAS Officer Sale 13,295 $2,639,253
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
27 analysts
Wolfe Research
2026-01-08
down
Outperform Peer Perform
Morgan Stanley
2025-12-12
Maintains
Overweight Overweight
HSBC
2025-12-10
up
Hold Buy
UBS
2025-11-07
Maintains
Neutral Neutral
Piper Sandler
2025-11-05
reit
Overweight Overweight
Citigroup
2025-11-03
Maintains
Neutral Neutral
JP Morgan
2025-11-03
Maintains
Overweight Overweight
Guggenheim
2025-10-20
Maintains
Buy Buy
Raymond James
2025-10-17
reit
Outperform Outperform
Piper Sandler
2025-10-10
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning ABBV from our newsroom.

Newest → oldest
TradingGPT V1 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Dashboard AI Chat Analysis Charts Profile